Mutants of Brucella melitensis

Details Mutants of Brucella melitensis Mutants of Brucella melitensis

1997-05-08

1999-08-17

Housel, James C.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

4242351, 4242341, 4241841, 424 931, 424 932, 435 41, 435 691, 4351723, 4352523, 4353201, A61K 3902, A01N 6300, C12P 100, C12P 2106

Patent

active

059390751

ABSTRACT:
The vaccines are prepared by isolating the Brucella genes complementing mutations in the purEK genes of Escherichia coli, physically mapping, determining the DNA sequence, constructing a defined deletion mutation by polynucleotide chain reaction (PCR), introducing a selectable marker into the deletion, and then selecting a purE mutant in Brucella arising by allelic exchange. The resulting Brucella require purines for growth because they lack the purE gene product that is required for the carboxylation of 5'-phosphoribosyl-5-aminoimidazole.

REFERENCES:
patent: 4735801 (1988-04-01), Stocker
Adams, Advances in Brucellosis Research. Chapter 17. pp. 250-276, 1990.
O'Callaghan et al. Injection and Immunity 56:419-423, 1988.
Smith et al. Injection and Immunity 55:2774-2776, 1987.
Houng et al. Abstracts of the 94th General Meeting of ASM. p. 133 Abstract D-208.
Essenberg Abstract of Grant and Progress Report. #0156434, OKL 01565 Dates Oct. 28, 1991 to Sep. 30, 1996.
Levine et al. J. Clin. Invest. 79:888-902, 1987.

Affiliated with

Also associated with

Rating

Mutants of Brucella melitensis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mutants of Brucella melitensis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutants of Brucella melitensis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-313093